Our top pick for
Athenex Inc is a drug manufacturers-specialty & generic business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 593 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.77|
|52-week range||$2.67 - $15.00|
|50-day moving average||$3.22|
|200-day moving average||$3.99|
|Wall St. target price||$7.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-07)||-2.81%|
|1 month (2021-09-16)||-22.19%|
|3 months (2021-07-16)||-30.40%|
|6 months (2021-04-16)||-30.23%|
|1 year (2020-10-16)||-77.86%|
|2 years (2019-10-17)||-74.35%|
|3 years (2018-10-17)||14.09|
|5 years (2016-10-13)||N/A|
|Revenue TTM||$120.2 million|
|Gross profit TTM||$49 million|
|Return on assets TTM||-23.44%|
|Return on equity TTM||-99.88%|
|Market capitalisation||$302.8 million|
TTM: trailing 12 months
There are currently 4.3 million Athenex shares held short by investors – that's known as Athenex's "short interest". This figure is 48.7% down from 8.3 million last month.
There are a few different ways that this level of interest in shorting Athenex shares can be evaluated.
Athenex's "short interest ratio" (SIR) is the quantity of Athenex shares currently shorted divided by the average quantity of Athenex shares traded daily (recently around 1.5 million). Athenex's SIR currently stands at 2.76. In other words for every 100,000 Athenex shares traded daily on the market, roughly 2760 shares are currently held short.
However Athenex's short interest can also be evaluated against the total number of Athenex shares, or, against the total number of tradable Athenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Athenex's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Athenex shares in existence, roughly 40 shares are currently held short) or 0.0627% of the tradable shares (for every 100,000 tradable Athenex shares, roughly 63 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Athenex.
Find out more about how you can short Athenex stock.
We're not expecting Athenex to pay a dividend over the next 12 months.
Over the last 12 months, Athenex's shares have ranged in value from as little as $2.67 up to $15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 0.6641. This would suggest that Athenex's shares are less volatile than average (for this exchange).
Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.